NCT04563377View on ClinicalTrials.gov

Safety and Immunogenicity of Candidate HIV Vaccines Given Sequentially

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

August 16, 2022

Study Completion Date

August 16, 2022

Conditions
Healthy
Interventions
BIOLOGICAL

ChAdOx1.HTI and MVA.HTI

ChAdOx1. HTI dose 5 x 10\^10 vp MVA.HTI dose 2 x 10\^8 pfu

Trial Locations (1)

OX3 7LE

Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford

All Listed Sponsors
lead

University of Oxford

OTHER

NCT04563377 - Safety and Immunogenicity of Candidate HIV Vaccines Given Sequentially | Biotech Hunter | Biotech Hunter